Skip to content

Epithalon vs GHK-Cu

Epithalon and GHK-Cu are both studied in the context of aging, but they target entirely different aging mechanisms. Epithalon focuses on telomere maintenance at the DNA level, while GHK-Cu modulates gene expression and tissue remodeling. They represent "inside-out" approaches to anti-aging research.

Side-by-Side Comparison

CategoryEpithalonGHK-Cu
Mechanism of actionActivates telomerase, the enzyme that maintains telomere length on chromosomes. Also reported to normalize melatonin production and modulate antioxidant enzyme activity.Copper-binding tripeptide that modulates expression of ~4,000 human genes. Promotes collagen synthesis, tissue remodeling, antioxidant enzyme production, and stem cell activity.
Primary research areaTelomere biology, biogerontology, circadian rhythm restoration. Studied extensively by the Khavinson group in St. Petersburg for age-related decline.Skin aging, wound healing, tissue remodeling, gene expression modulation. Studied by Pickart et al. for broad anti-aging gene activation.
Evidence levelHuman studies by Khavinson et al. including a notable elderly cohort study showing reduced mortality over 6-8 years. However, these studies have methodological limitations and have not been replicated by independent groups. Primarily Russian research.Human data for topical wound healing. Broad gene expression studies published. GHK-Cu levels decline naturally with age (measurable in human plasma). More internationally replicated research.
Administration routeSubcutaneous injection. Typically administered in short cycles (10-20 days) a few times per year.Subcutaneous injection or topical. Topical is well-studied for skin applications.
Typical research dosing5-10 mg daily subcutaneous for 10-20 days. Cycled 2-3 times per year. Based on Khavinson protocols.Injectable: 1-3 mg daily subcutaneous. Topical: applied to target area. 4-8 week cycles.
Key studies/evidenceKhavinson & Morozov (2003) — elderly cohort study with Epithalon showing reduced mortality. Anisimov et al. — animal studies on telomerase activation and lifespan extension. Limited independent replication.Pickart et al. — extensive gene expression studies. Published human wound healing data. Well-characterized decline with aging in human plasma. More robust international research base.

Can They Be Stacked?

Yes — complementary mechanisms

Considered complementary: Epithalon targets aging at the DNA level (telomeres), while GHK-Cu addresses aging at the tissue and gene expression level. Often described as "inside-out anti-aging." No published studies on this combination.

Verdict

GHK-Cu has a broader and more internationally validated evidence base, with measurable age-related decline in humans and published gene expression data. Epithalon's human studies are intriguing but come primarily from one research group with limited independent replication. GHK-Cu is better for visible aging (skin, tissue quality), while Epithalon targets cellular aging at the telomere level. Both lack large-scale clinical trials for anti-aging indications.

Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.